UniQure NV (NASDAQ: QURE) is a biotechnology company focused on developing gene therapies. It aims to provide innovative treatments for patients with severe genetic diseases. The company is a key player in the biotech industry, competing with other firms that are also exploring gene therapy solutions.
On September 25, 2025, Cantor Fitzgerald upgraded QURE's stock to "Overweight," with the stock priced at $47.50. This upgrade came with a raised price target from $47 to $80, reflecting confidence in the company's potential. The stock's recent performance supports this optimism.
UniQure's stock experienced a 248% surge in a single session, driven by successful trial results for its gene therapy targeting Huntington's disease. This propelled the stock to a five-year high, marking its most successful session. Analysts believe this could be the start of a sustained rally.
Stifel and Leerink have increased their price targets for QURE to $65 and $68, respectively. Mizuho doubled its target to $60, citing strong performance on secondary endpoints and describing the results as "game-changing." These adjustments suggest the market may be underestimating UniQure's potential.
Currently, QURE is priced at $50.62, up 6.57% with a $3.12 change. The stock has fluctuated between $46.56 and $54.98 today. Over the past year, it reached a high of $54.97 and a low of $4.45. With a market cap of $2.78 billion and a trading volume of 9.21 million shares, UniQure is gaining significant attention.
